Ultromics

Ultromics joined the Lightrock portfolio in 2025. It is a provider of AI-driven cardiology solutions that support clinicians in detecting heart diseases faster and more accurately.

Ultromics is headquartered in Oxford, UK. Its FDA-approved EchoGo® platform algorithms help to detect heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis, two of the most challenging and underdiagnosed forms of heart disease. The platform is trained on one of the largest real-world echo datasets globally and is shown to outperform existing standards of care.